Imọ Itọsọna

ADMET and Toxicity Prediction

ADMET prediction estimates absorption, distribution, metabolism, excretion, and toxicity properties from molecular structure or other data.

  • 3 min ka
  • kẹhin imudojuiwọn
Lori iwe yi3 min ka
  1. Akopọ
  2. Jin Dive
  3. Ipa Ilana
  4. The Future of ADMET and Toxicity Prediction
  5. Real-World imuse
  6. Awọn ewu & Awọn ọna iṣọ
  7. Ilana Ilana imuse
  8. Tesiwaju Ṣiṣawari
  9. Awọn ibeere ti a beere nigbagbogbo

Akopọ

These models can help prioritize compounds for experiments, but predictions are endpoint-specific and require domain-aware validation rather than being treated as proof of safety or drug suitability.

Jin Dive

ADMET is a collection of pharmacokinetic and safety properties: absorption, distribution through the body, metabolism, excretion, and toxicity. Different endpoints measure different biological processes, such as solubility, permeability, plasma protein binding, metabolic stability, clearance, or a particular toxicity assay. There is no single ADMET score that proves a compound is suitable for humans. Machine-learning models learn from experimental datasets or curated databases using molecular fingerprints, descriptors, graphs, or learned representations. Labels can be noisy because assays vary in protocol, cell line, organism, concentration, and measurement units. Some datasets combine values from different sources or convert continuous measurements into categories. Endpoint definitions and unit conversions should be checked before training. Evaluation must reflect the intended use. Random splits can place close analogs in training and test sets, making prediction easier than for new chemical scaffolds. Scaffold-based, temporal, or external splits can better probe generalization, depending on the question. Class imbalance, censored values, repeated compounds, and assay leakage also need attention. Report uncertainty and the model's applicability domain: whether a candidate resembles the chemistry and conditions used for training. A positive model prediction is a hypothesis for follow-up, not experimental evidence. Use models to prioritize tests, compare with baselines, and identify compounds where predictions are uncertain or endpoints disagree. High-stakes toxicology decisions require appropriate assays and expert review. A model trained on one endpoint cannot establish broader safety or human outcomes. OECD guidance on QSAR model validation emphasizes a defined endpoint, unambiguous algorithm, defined applicability domain, appropriate measures of goodness-of-fit and predictivity, and mechanistic interpretation where possible. These principles help make structure-activity predictions more transparent. Maintain data provenance and versioning so predictions can be traced to assays, structures, and model configurations.

Ipa Ilana

Iye owo ati isuna

Awọn ipinnu faaji ṣe awakọ iṣẹ ati idiyele iṣẹ fun awọn ọdun.

Awọn ipinnu diẹ sii

Ẹkọ imọ-ẹrọ ṣe iranlọwọ fun awọn ẹgbẹ lati yan akopọ to tọ, kii ṣe ọkan tuntun nikan.

Iṣakoso didara

Awọn yiyan imọ-ẹrọ to dara julọ dinku awọn iṣẹlẹ igbẹkẹle ni iṣelọpọ.

The Future of ADMET and Toxicity Prediction

ADMET models may improve as datasets capture richer assay context, chemical domains, and uncertainty. Integrating predictions across endpoints could help prioritize experiments, but it can also hide disagreements if combined into one score. Regulatory and scientific practice will continue to require transparent validation and domain limits. Experimental assays and expert review will remain central to safety assessment. Better assay context may improve transfer between datasets, but endpoint definitions will remain important. New models should report uncertainty and chemical scope so experimental teams can choose appropriate follow-up.

Real-World imuse

A discovery team ranks compounds by a predicted solubility endpoint and sends selected structures for an appropriate laboratory assay.

A toxicology group checks whether a new molecule lies within the chemistry domain represented by its training compounds.

An analyst distinguishes predictions for liver metabolism from separate endpoints for cardiac, genetic, or acute toxicity.

A model report includes assay source, endpoint definition, uncertainty, and an external evaluation split.

Awọn ewu & Awọn ọna iṣọ

  • Ṣiṣepe ala-ilẹ kan le tọju awọn ailagbara eto ti o gbooro.

  • Awọn ohun elo amayederun ati awọn idiyele itọju nigbagbogbo ni aibikita.

  • Aabo ati awọn ela akiyesi le dagba bi awọn eto ṣe di eka sii.

Ilana Ilana imuse

  1. Ṣetumo lairi, didara, ati awọn ibi-afẹde idiyele ṣaaju imuse.

  2. Aṣepari labẹ ẹru ojulowo ati awọn ipo data.

  3. Abojuto ohun elo fun awọn aṣiṣe, fiseete, ati ipa olumulo.

  4. Mura ipadasẹhin pada ati awọn ipa ọna esi iṣẹlẹ ṣaaju iwọn.

Tesiwaju Ṣiṣawari

Free newsletter

Get the daily AI briefing

Three verified AI stories every weekday morning, written in plain English. Free forever, no ads.

One email each weekday. Unsubscribe in one click. We never sell or share your address.

Test yourself

Take the ADMET and Toxicity Prediction quiz

Instant feedback on every answer, and a shareable certificate with a verifiable ID once you pass a course.

Bẹrẹ adanwo

Support free AI education. AI Understanding is a 501(c)(3) nonprofit — no ads, no paywall, ever. Make a donation

Awọn ibeere ti a beere nigbagbogbo

What is ADMET and Toxicity Prediction?

ADMET prediction estimates absorption, distribution, metabolism, excretion, and toxicity properties from molecular structure or other data. These models can help prioritize compounds for experiments, but predictions are endpoint-specific and require domain-aware validation rather than being treated as proof of safety or drug suitability.

Why are ADMET predictions endpoint-specific?

Solubility, clearance, permeability, and toxicity are different endpoints.

Why can a random molecular split overstate performance on new chemical scaffolds?

Close structures across partitions can make test predictions easier.

What does an applicability domain describe?

Applicability domain indicates whether a candidate resembles the model's training conditions.

Why document assay source and protocol with training labels?

Assay variation and endpoint definitions affect label consistency.

What does a positive predicted safety result establish?

Predictions are not equivalent to experimental or clinical evidence.